FDA Approves a New Antibody Drug to Prevent RSV in Babies

• 2023

  Log in to bookmark this resource.

  Log in
• Pien Huang

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

This news brief announces the Food and Drug Administration's (FDA) approval of nirsevimab. The antibody drug, marketed as Beyfortus by AstraZeneca and Sanofi, reduces medical care needs for RSV by 70-75% in infants. It is approved for use during their first two RSV seasons. Nirsevimab offers longer protection compared to the older palivizumab shot.

---

Tags

Focus Area: Infectious Disease

Audiences: Families & Children; Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Drug Approval; Antibodies, Monoclonal, Humanized

Institutions: National Public Radio (NPR)

---

More like this

Candida auris (C. auris) None · Centers for Disease Control and Prevention (CDC) Drug Trials Snapshots: BEYFORTUS 2024 · U.S. Food and Drug Administration Measles: What Parents Need to Know 2024 · Healthy Children

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---